7Moroz A, Delella FK, Lacorte LM, et al. Fibronectin induces MMP2 expression in human prostate cancer cells [ J ]. Biochem Biophys Res Commun, 2013, 430(4) : 1319 -1321.
8Gao J, Ding F, Liu Q, et al. Knockdown of MACC1 expression suppressed hepatocellular carcinoma cell migration and invasion and inhibited expression of MMP2 and MMP9 [ J ]. Mol Cell Biochem, 2013, 376(1 -2): 21 -32.
8Buadi FK, Heyman MR, Gocke CD, et al. Treatment and outcomes of post-transplant lymphoproliferative disease: a single institution study [J]. Am J Hematol, 2007, 82(3): 208-14.
9Cacciarelli TV, Reyes J, Jaffe R, et al. Primary tacrolimus (FK506) therapy and the long-term risk of post-transplant lymphoproliferative disease in pediatric liver transplant recipients [J]. Pediatr Transplant, 2001, 5(5): 359-64.
10Capello D, Rossi D, Gaidano G. Post-transplant lymphoproliferative disorders: molecular basis of disease histogenesis and pathogenesis [J]. Hematol Oncol, 2005, 23(2): 61-7.
4Maes W, Van Gool SW. Experimental immunotherapy for malignant glioma: lessons from two decades of research in the GL261 model [J]. Cancer Immunal Immunother, 2013,60(2) : 153 -160.
5Kgel D, Fulda S, Mittelbronn M. Therapeutic exploration of apoptosis and autophagy for glioblastoma [ J]. Anticancer Agents Med Chem, 2010, 10(6) : 438 -449.
6Lee EQ, Puduvalli VK, Reid JM, et al. Phase istudy of vorinostat in patients with temozolomide in patients with high-grade gliomas: North American brain tumor consortium study 04-03 [ J]. Clin Cancer Res, 2012, 18(21) : 6032 -6039.
